Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV004579887 | SCV005063886 | likely pathogenic | Glycogen storage disease, type II | 2020-10-10 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Arg672 amino acid residue in GAA. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 9535769, 15986226, 9535769, 23884227, 11053688, 28592009, 25712382, 9535769, 19862843). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. This variant has not been reported in the literature in individuals with GAA-related conditions. This variant is an in-frame deletion of the genomic region encompassing part of exon 13, exons 14-16, and part of exon 17 (c.1763_2434del) of the GAA gene. It preserves the integrity of the reading frame. |